UroGen Pharma Net Worth
UroGen Pharma Net Worth Breakdown | URGN |
UroGen Pharma Net Worth Analysis
UroGen Pharma's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including UroGen Pharma's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of UroGen Pharma's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform UroGen Pharma's net worth analysis. One common approach is to calculate UroGen Pharma's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares UroGen Pharma's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing UroGen Pharma's net worth. This approach calculates the present value of UroGen Pharma's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of UroGen Pharma's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate UroGen Pharma's net worth. This involves comparing UroGen Pharma's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into UroGen Pharma's net worth relative to its peers.
Enterprise Value |
|
To determine if UroGen Pharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding UroGen Pharma's net worth research are outlined below:
| UroGen Pharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 90.4 M. Net Loss for the year was (126.87 M) with profit before overhead, payroll, taxes, and interest of 81.52 M. | |
| UroGen Pharma currently holds about 111.74 M in cash with (96.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.91. | |
| UroGen Pharma has a frail financial position based on the latest SEC disclosures | |
| Over 87.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Dong Kim of 7500 shares of UroGen Pharma subject to Rule 16b-3 |
UroGen Pharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in UroGen Pharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to UroGen Pharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
UroGen Pharma Target Price Consensus
UroGen target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. UroGen Pharma's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 6 | Strong Buy |
Most UroGen analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand UroGen stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of UroGen Pharma, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationUroGen Pharma Target Price Projection
UroGen Pharma's current and average target prices are 11.53 and 39.93, respectively. The current price of UroGen Pharma is the price at which UroGen Pharma is currently trading. On the other hand, UroGen Pharma's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
UroGen Pharma Market Quote on 19th of March 2025
Target Price
Analyst Consensus On UroGen Pharma Target Price
Know UroGen Pharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as UroGen Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading UroGen Pharma backward and forwards among themselves. UroGen Pharma's institutional investor refers to the entity that pools money to purchase UroGen Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Diadema Partners Lp | 2024-12-31 | 50 K | Llbh Private Wealth Management, Llc | 2024-12-31 | 39 K | Alps Advisors Inc | 2024-12-31 | 34.1 K | Tidal Investments Llc. | 2024-12-31 | 30.5 K | Jpmorgan Chase & Co | 2024-12-31 | 21.1 K | Vivaldi Capital Management, Llc | 2024-12-31 | 20.1 K | Susquehanna Fundamental Investments, Llc | 2024-12-31 | 19.5 K | Legal & General Group Plc | 2024-09-30 | 15.9 K | Aquatic Capital Management Llc | 2024-12-31 | 9.4 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 2.2 M | Vestal Point Capital Lp | 2024-12-31 | 1.6 M |
Follow UroGen Pharma's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 527.78 M.Market Cap |
|
Project UroGen Pharma's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.44) | (0.47) | |
| Return On Capital Employed | (0.40) | (0.42) | |
| Return On Assets | (0.44) | (0.47) | |
| Return On Equity | 14.41 | 15.13 |
When accessing UroGen Pharma's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures UroGen Pharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of UroGen Pharma's profitability and make more informed investment decisions.
Evaluate UroGen Pharma's management efficiency
UroGen Pharma has return on total asset (ROA) of (0.2578) % which means that it has lost $0.2578 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (14.8126) %, meaning that it created substantial loss on money invested by shareholders. UroGen Pharma's management efficiency ratios could be used to measure how well UroGen Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of March 2025, Return On Equity is likely to grow to 15.13, while Return On Tangible Assets are likely to drop (0.47). At this time, UroGen Pharma's Total Assets are very stable compared to the past year. As of the 19th of March 2025, Other Current Assets is likely to grow to about 10.4 M, though Net Tangible Assets are likely to grow to (97.6 M).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.21) | (0.20) | |
| Tangible Book Value Per Share | (0.21) | (0.20) | |
| Enterprise Value Over EBITDA | (3.70) | (3.51) | |
| Price Book Value Ratio | (51.87) | (49.28) | |
| Enterprise Value Multiple | (3.70) | (3.51) | |
| Price Fair Value | (51.87) | (49.28) | |
| Enterprise Value | 367.2 M | 209.5 M |
At UroGen Pharma, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Enterprise Value Revenue 4.5851 | Revenue | Quarterly Revenue Growth 0.044 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific UroGen Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on UroGen Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases UroGen Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
UroGen Pharma Corporate Filings
| 17th of March 2025 Other Reports | ViewVerify | |
8K | 10th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 4th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 18th of November 2024 An amendment to the original Schedule 13D filing | ViewVerify |
UroGen Pharma Earnings Estimation Breakdown
The calculation of UroGen Pharma's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of UroGen Pharma is estimated to be -0.795 with the future projection ranging from a low of -0.96 to a high of -0.37. Please be aware that this consensus of annual earnings estimates for UroGen Pharma is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.96 Lowest | Expected EPS | -0.37 Highest |
UroGen Pharma Earnings Projection Consensus
Suppose the current estimates of UroGen Pharma's value are higher than the current market price of the UroGen Pharma stock. In this case, investors may conclude that UroGen Pharma is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and UroGen Pharma's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 7 | 85.11% | -0.8 | -0.795 | -2.96 |
UroGen Pharma Earnings per Share Projection vs Actual
Actual Earning per Share of UroGen Pharma refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering UroGen Pharma predict the company's earnings will be in the future. The higher the earnings per share of UroGen Pharma, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.UroGen Pharma Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as UroGen Pharma, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of UroGen Pharma should always be considered in relation to other companies to make a more educated investment decision.UroGen Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact UroGen Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-03-12 | 2024-12-31 | -0.72 | -0.8 | -0.08 | 11 | ||
2024-11-06 | 2024-09-30 | -0.82 | -0.55 | 0.27 | 32 | ||
2024-08-13 | 2024-06-30 | -0.83 | -0.91 | -0.08 | 9 | ||
2024-05-13 | 2024-03-31 | -0.87 | -0.97 | -0.1 | 11 | ||
2024-03-14 | 2023-12-31 | -0.68 | -0.72 | -0.04 | 5 | ||
2023-11-14 | 2023-09-30 | -0.85 | -0.68 | 0.17 | 20 | ||
2023-08-10 | 2023-06-30 | -1.14 | -1.03 | 0.11 | 9 | ||
2023-05-11 | 2023-03-31 | -1.33 | -1.3 | 0.03 | 2 | ||
2023-03-16 | 2022-12-31 | -1.07 | -1.22 | -0.15 | 14 | ||
2022-11-10 | 2022-09-30 | -1.16 | -1.13 | 0.03 | 2 | ||
2022-08-11 | 2022-06-30 | -1.27 | -1.18 | 0.09 | 7 | ||
2022-05-10 | 2022-03-31 | -1.33 | -1.25 | 0.08 | 6 | ||
2022-03-21 | 2021-12-31 | -1.17 | -1.27 | -0.1 | 8 | ||
2021-11-15 | 2021-09-30 | -1.29 | -1.35 | -0.06 | 4 | ||
2021-08-04 | 2021-06-30 | -1.13 | -1.17 | -0.04 | 3 | ||
2021-05-13 | 2021-03-31 | -1.29 | -1.17 | 0.12 | 9 | ||
2021-03-18 | 2020-12-31 | -1.37 | -1.38 | -0.01 | 0 | ||
2020-11-09 | 2020-09-30 | -1.49 | -1.31 | 0.18 | 12 | ||
2020-08-10 | 2020-06-30 | -1.58 | -1.44 | 0.14 | 8 | ||
2020-05-07 | 2020-03-31 | -1.62 | -1.79 | -0.17 | 10 | ||
2020-03-02 | 2019-12-31 | -1.7 | -1.86 | -0.16 | 9 | ||
2019-11-12 | 2019-09-30 | -1.29 | -1.06 | 0.23 | 17 | ||
2019-08-09 | 2019-06-30 | -1.22 | -1.08 | 0.14 | 11 | ||
2019-05-09 | 2019-03-31 | -1.14 | -1.11 | 0.03 | 2 | ||
2019-02-28 | 2018-12-31 | -1.24 | -1.46 | -0.22 | 17 | ||
2018-11-12 | 2018-09-30 | -1.05 | -1.28 | -0.23 | 21 | ||
2018-08-14 | 2018-06-30 | -0.89 | -1.14 | -0.25 | 28 | ||
2018-05-15 | 2018-03-31 | -0.72 | -0.88 | -0.16 | 22 | ||
2018-03-15 | 2017-12-31 | -0.62 | -0.74 | -0.12 | 19 | ||
2017-11-14 | 2017-09-30 | -0.05 | -0.02 | 0.03 | 60 | ||
2017-08-14 | 2017-06-30 | -0.57 | -0.7 | -0.13 | 22 |
UroGen Pharma Corporate Management
| Dong Kim | Chief Officer | Profile | |
| Jason JD | Chief Counsel | Profile | |
| Sari PrutchiSagiv | Marketing Director | Profile | |
| Jason Smith | Chief Counsel | Profile | |
| Bryon Wornson | Advocacy Talent | Profile | |
| Eric Zanten | Director Communications | Profile | |
| Christopher CPA | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.96) | Revenue Per Share | Quarterly Revenue Growth 0.044 | Return On Assets | Return On Equity |
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.